vTv Therapeutics (VTVT) EBITDA (2014 - 2026)

vTv Therapeutics (VTVT) has 13 years of EBITDA data on file, last reported at $23.3 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA rose 457.73% year-over-year to $23.3 million; the trailing twelve-month figure through Mar 2026 stood at -$3.0 million (up 87.86% YoY), and the FY2025 full-year result was -$32.8 million, down 35.68% from the prior year.
• EBITDA grew to $23.3 million in Q1 2026, from -$7.9 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $23.3 million in Q1 2026 to a low of -$10.7 million in Q3 2025.
• A 5-year average of -$4.8 million and a median of -$6.5 million in 2022 frame the typical range for EBITDA.
• Across the five-year window, EBITDA slumped 254.9% in 2022 and surged 457.73% in 2026, its largest moves.
• Tracing VTVT's EBITDA over 5 years: stood at -$6.3 million in 2022, then rose by 25.79% to -$4.7 million in 2023, then slipped by 3.93% to -$4.9 million in 2024, then tumbled by 61.18% to -$7.9 million in 2025, then soared by 395.03% to $23.3 million in 2026.
• Business Quant data shows VTVT's EBITDA at $23.3 million in Q1 2026, -$7.9 million in Q4 2025, and -$10.7 million in Q3 2025.